Image credit: Canva
Mutations involving BRCA1-Associated Protein-1 (BAP1), a structure involved in epigenetic regulation of gene expression, DNA repair and cellular energetics, have emerged as common mutations in malignant mesotheliomas. These mutations also predispose individuals to melanomas, as well as lung, renal, gastric, breast and hepatobiliary carcinomas. A clinical trial led by David S. Schrump, M.D., M.B.A., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination drug therapy for BRCA1-Associated Protein-1 mutations.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Deneise Francis, R.N., at (240) 328-2693 or deneise.francis@nih.gov.
Clinicaltrials.gov identifier: NCT05960773
NCI Protocol ID: IRB001549
Official Title: Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.